Mini-tablets as technological strategy for modified release of morphine sulfate

Abstract This study aimed to use an intelligent formulation design for the development of mini-tablets for the modified release of morphine sulfate. A formulation (F1) was proposed using the Hiperstart® software. Based on the suggested formulation, two other formulations (F2 and F3) were prepared: one for modified and another for immediate drug release. The powders were characterized as bulk and tapped density, Hausner’s factor, and compressibility index analyses. Mini-tablets were directly compressed and characterized by hardness, friability, size, and weight variation. The in vitro drug release profile was carried out according to apparatus 1 of USP. Formulations showed good flow properties, and the mini-tablets displayed characteristics according to the specified. In comparison to F3 (immediate release), F1 and F2 displayed slower drug release time, showing the efficiency of the matrix formed. F3 displayed 90% of drug released up to 10 min, while F1 and F2 required 240 min. The results highlight the importance to use intelligent formulation design for the development of improved mini-tablet matrices. Formulation F1 was found to be suitable for modified morphine sulfate release. Further studies with more formulations are necessary for the production of optimized mini-tablets with suitable prolonged morphine sulfate release.

[1]  S. Gautam,et al.  Morphine Sustained Release Tablets Becoming Ghost Pill: A Palliative Conundrum , 2022, Indian journal of palliative care.

[2]  P. Kleinebudde,et al.  Tableting of mini-tablets in comparison with conventionally sized tablets: A comparison of tableting properties and tablet dimensions , 2020, International journal of pharmaceutics: X.

[3]  Anjali Agrawal,et al.  Development of Low Dose Micro-tablets by High Shear Wet Granulation Process. , 2020, International journal of pharmaceutics.

[4]  Kuldip B. Patel,et al.  Decoding the Small Size Challenges of Mini-tablets for Enhanced Dose Flexibility and Micro-dosing. , 2019, International journal of pharmaceutics.

[5]  J. Breitkreutz,et al.  Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial , 2018, The Journal of pediatrics.

[6]  H. Ferraz,et al.  Physical characterization of multiparticulate systems , 2018 .

[7]  R. C. Moreton.  United States Pharmacopeia-National Formulary , 2016 .

[8]  P. Klepstad,et al.  The evidence of neuraxial administration of analgesics for cancer‐related pain: a systematic review , 2015, Acta anaesthesiologica Scandinavica.

[9]  J. Breitkreutz,et al.  Acceptability of Uncoated Mini-Tablets in Neonates--A Randomized Controlled Trial. , 2015, The Journal of pediatrics.

[10]  A. McLean.  Is a Single Entry Training Scheme for Intensive Care Medicine Both Inevitable and Desirable?* , 2015, Critical care medicine.

[11]  N. Nafee,et al.  Mini-tablets versus pellets as promising multiparticulate modified release delivery systems for highly soluble drugs. , 2015, International journal of pharmaceutics.

[12]  A. Jain,et al.  The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Roland Bodmeier,et al.  The effect of polymer properties on direct compression and drug release from water-insoluble controlled release matrix tablets. , 2014, International journal of pharmaceutics.

[14]  Jörg Breitkreutz,et al.  Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. , 2013, The Journal of pediatrics.

[15]  Pharmaceutical Press,et al.  Handbook of Pharmaceutical Excipients , 2012 .

[16]  Loyd V. Allen,et al.  Ansel'S Pharmaceutical Dosage Forms And Drug Delivery Systems , 2007 .

[17]  P. Kleinebudde,et al.  Development of mini-tablets with 1mm and 2mm diameter. , 2011, International journal of pharmaceutics.

[18]  A. Trescot,et al.  Extended-release morphine sulfate in treatment of severe acute and chronic pain , 2010, Journal of pain research.

[19]  C. Wongvipaporn,et al.  Formulation Development of Morphine Sulfate Sustained-Release Tablets and Its Bioequivalence Study in Healthy Thai Volunteers , 2010, AAPS PharmSciTech.

[20]  M. Ishida,et al.  A novel approach to sustained pseudoephedrine release: differentially coated mini-tablets in HPMC capsules. , 2008, International journal of pharmaceutics.

[21]  B. Nicholson.  Morphine sulfate extended-release capsules for the treatment of chronic, moderate-to-severe pain , 2008 .

[22]  F. Veiga,et al.  In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[23]  D. Duarte.  [Opium and opioids: a brief history.]. , 2005, Revista brasileira de anestesiologia.

[24]  Jennifer B Dressman,et al.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  B. Mccarberg,et al.  Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. , 2001, American journal of therapeutics.

[26]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  C Vervaet,et al.  Matrix mini-tablets based on starch/microcrystalline wax mixtures. , 2000, International journal of pharmaceutics.

[28]  Anthony J. Hickey,et al.  The physics of powder flow : Applied to pharmaceutical solids , 2000 .

[29]  J. B. Mielck,et al.  Minitabletting: improving the compactability of paracetamol powder mixtures , 1998 .

[30]  Thomas O'Hara,et al.  A REVIEW OF METHODS USED TO COMPARE DISSOLUTION PROFILE DATA , 1998 .

[31]  J. L. Gómez-Amoza,et al.  Comparison of a spray-dried α-lactose monohydrate with a fully hydrated roller-dried β-lactose , 1996 .

[32]  J. Hasselström,et al.  Morphine Pharmacokinetics and Metabolism in Humans , 1993, Clinical pharmacokinetics.

[33]  Umesh V. Banakar,et al.  Pharmaceutical Dissolution Testing , 1991 .

[34]  M Trávnícková,et al.  European pharmacopoeia. , 1970, British medical journal.

[35]  J. Gaddum,et al.  United States Pharmacopeia , 1955, Nature.

[36]  E. Johnson.  Dissolution , 1885, The Dental register.

[37]  E. Hershberg.  APPARATUS FOR PUNCHING MINIATURE TABLETS , 2017 .

[38]  M. Aulton.  Pharmaceutics : the science of dosage form design , 2002 .

[39]  D. Rodrigues,et al.  In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets. , 1998, Drug development and industrial pharmacy.

[40]  P. Buri,et al.  Cellulose Matrices for Zero-Order Release of Soluble Drugs , 1988 .

[41]  H. Hausner.  FRICTION CONDITIONS IN A MASS OF METAL POWDER. , 1967 .